Key Laboratory of Beijing for Nonclinical Safety Evaluation Research of Drugs, National Center for Safety Evaluation of Drugs, National Institutes for Food and Drug Control, A8 Hongda Middle Road, Beijing, Economic-Technological Development Area, Beijing, 100176, People's Republic of China.
Sinoneural Cell Engineering Group Co., Ltd., Shanghai, People's Republic of China.
Sci Rep. 2024 May 28;14(1):12251. doi: 10.1038/s41598-024-63118-4.
Mesenchymal stem cells (MSCs) have demonstrated promising advantages in the therapies of many diseases, while its multi-directional differentiation potential and immunotoxicity are the major concerns hindered their clinical translation. In this study, human umbilical Mesenchymal stem cell (hUC-MSCs) were labeled with a near-infrared fluorescent dye DiR before infused into cynomolgus monkeys, and the amount of hUC-MSCs in the peripheral blood were dynamically estimated from 5 min to 28 days post a single administration at 3 × 10 cells/kg and 2 × 10 cells/kg intravenously. As results, some hUC-MSCs distributed to the whole body within 5 min, while most of the cells accumulate in the lungs along with the systemic blood circulation, and subsequently released into the blood. The toxicity potentials of hUC-MSCs were investigated in another 30 cynomolgus monkeys, and the cells were repeatedly administrated at doses of 3 × 10cells/kg and 2 × 10 cells/kg for 5 times on a weekly basis, with a recovery period of 1 months. hUC-MSCs showed no obvious toxic effects in cynomolgus monkeys, except xenogeneic immune rejection to human stem cells. Low levels of the hUC-MSC gene were detected in the peripheral blood of a few animals administered 2 × 10 cells/kg at 30 min subsequent to the first and last administration, and there was no significant difference in the copy number of the hUC-MSC gene in the blood samples compared with the first and last administration, indicating that the hUC-MSC was not significantly amplified in vivo, and it its safe in non-human primates. Our study for the first time verified the safety of long-term use of hUC-MSCs in primates. We have pioneered a technology for the real-time detection of hUC-MSCs in peripheral blood and provide dynamicand rapid monitoring of the distribution characteristics of hUC-MSCs in vivo. Here, we provide data supporting the application of such products for clinical treatment and the application of stem cells in major refractory diseases and regenerative medicine.
间充质干细胞(MSCs)在许多疾病的治疗中显示出有前景的优势,而其多向分化潜能和免疫毒性是阻碍其临床转化的主要关注点。在这项研究中,人脐带间充质干细胞(hUC-MSCs)在输注到食蟹猴前用近红外荧光染料 DiR 标记,并且在单次静脉注射 3×10 细胞/kg 和 2×10 细胞/kg 后,从 5 分钟到 28 天动态估计外周血中的 hUC-MSCs 数量。结果,一些 hUC-MSCs 在 5 分钟内分布到全身,而大多数细胞随着全身血液循环积聚在肺部,随后释放到血液中。在另外 30 只食蟹猴中研究了 hUC-MSCs 的毒性潜能,细胞以 3×10 细胞/kg 和 2×10 细胞/kg 的剂量每周重复给药 5 次,每次给药间隔 1 个月。hUC-MSCs 除了对人干细胞的异种免疫排斥外,在食蟹猴中没有明显的毒性作用。在首次和末次给药后 30 分钟,少数给予 2×10 细胞/kg 的动物的外周血中检测到 hUC-MSC 基因的低水平,与首次和末次给药相比,血液样本中 hUC-MSC 基因的拷贝数没有显著差异,表明 hUC-MSC 在体内没有显著扩增,在非人类灵长类动物中是安全的。我们的研究首次验证了 hUC-MSCs 在灵长类动物中长期使用的安全性。我们开创了一种实时检测外周血中 hUC-MSCs 的技术,并提供了体内 hUC-MSCs 分布特征的动态快速监测。在这里,我们提供的数据支持了此类产品在临床治疗中的应用,以及干细胞在重大难治性疾病和再生医学中的应用。